Combined immunotherapy drugs ‘could treat most common form of bowel cancer’
A combination of two immunotherapy drugs could be used to treat the most common form of bowel cancer, scientists have said, after trials showed tumours had shrunk or remained stable in three out of five patients.
Botensilimab and balstilimab could “offer new hope” for those diagnosed with a type of cancer that has previously not said.
